.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
US Army
US Department of Justice
McKesson
Farmers Insurance
Julphar
Boehringer Ingelheim
Cerilliant
Johnson and Johnson

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Medical use for tachykinin antagonists
Abstract: The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. ##STR00001## wherein R represents the ring A ##STR00002## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from halogen atoms and C.sub.1-4alkyl, C.sub.1-4alkoxy, trifluoromethyl, and S(O).sub.nC.sub.1-4alkyl groups; R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C.sub.1-4alkyl, C.sub.1-4alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
Inventor(s): Hagan; Russell Michael (Ware, GB), Bunce; Keith Thomas (Ware, GB)
Assignee: Glaxo Group Limited (Middlesex, GB)
Filing Date:Nov 18, 2004
Application Number:10/990,462
Claims:1. A method for the treatment of a mammal suffering from or susceptible to emesis, comprising: administering to said mammal a 5HT.sub.3 receptor antagonist selected from the group consisting of ondansetron, granisetron and metoclopramide; and an NK.sub.1 receptor antagonist which is cis-3-(2-methoxybenzyl)amino-2-phenylpiperidine or a pharmaceutically acceptable salt.

2. The method according to claim 1, wherein the cis-3-(2-methoxybenzyl)amino-2-phenlypiperidine or pharmaceutically acceptable salt thereof is administered in an amount from about 0.1 to 400 mg per kg body weight of the subject being treated per day and the 5HT.sub.3 receptor antagonist is administered in an effective amount.

3. The method according to claim 2, wherein the cis-3-(2-methoxybenzyl)amino-2-phenlypiperidine or pharmaceutically acceptable salt thereof is administered at a dose of 3 mg/kg.

4. The method according to claim 2, wherein the cis-3-(2-methoxybenzyl)amino-2-phenlypiperidine or pharmaceutically acceptable salt thereof is administered at a dose of 5 mg/kg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Dow
Deloitte
Daiichi Sankyo
McKesson
Accenture
Medtronic
Chinese Patent Office
Citi
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot